Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials
Breast. 2024 Apr 4;75:103729. doi: 10.1016/j.breast.2024.103729. Online ahead of print.ABSTRACTOver the past few decades, first-line therapy for treating advanced and metastatic HR+/HER2-breast cancer has transformed due to the introduction of adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). However, there is an unmet need for novel classes of endocrine therapy with superior efficacy to improve treatment outcomes and overcome CDK4/6i resistance. New generation selective estrogen receptor degraders (SERDs), orally administered and with higher bioavailability, could potentially be the novel ...
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Kleoniki Apostolidou Eleni Zografos Maria Alkistis Papatheodoridi Oraianthi Fiste Meletios Athanasios Dimopoulos Flora Zagouri Source Type: research
The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer
CONCLUSIONS: Nonadherence was high in the current sample, and significantly more likely in participants reporting overall severe symptoms. Clinicians should be aware of the scale of common side effects and facilitate open conversation about potential barriers to adherence. Follow-up care should include assessment of common symptoms and signpost patients to appropriate support or treatment when required. Future research should explore potential for a central symptom to act as a target for intervention, to relieve overall side effect burden and facilitate better medication adherence.PMID:38599048 | DOI:10.1016/j.breast.2024....
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Sommer Agnew Megan Crawford Iain MacPherson Victor Shiramizu Leanne Fleming Source Type: research
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature
CONCLUSION: The study showed that a subgroup of patients with a clinical high risk and a genomic low risk ER+/HER2-breast cancer benefits from NET resulting in BCS instead of a mastectomy. Additionally, NET may enable de-escalation in axillary treatment.PMID:38599047 | DOI:10.1016/j.breast.2024.103726 (Source: Breast)
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Josefien P van Olmen Chaja F Jacobs Sanne A L Bartels Claudette E Loo Joyce Sanders Marie-Jeanne T F D Vrancken Peeters Caroline A Drukker Frederieke H van Duijnhoven Marleen Kok Source Type: research
Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance
Cancer Discov. 2024 Apr 10:OF1-OF3. doi: 10.1158/2159-8290.CD-24-0282. Online ahead of print.ABSTRACTRosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro. See related article by Rosano et al. (9).PMID:38598672 | DOI:10.1158/2159-8290.CD-24-0282 (Source: Cancer Control)
Source: Cancer Control - April 10, 2024 Category: Cancer & Oncology Authors: Arnau Llinas-Bertran Meritxell Bellet-Ezquerra Jose A Seoane Source Type: research
Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials
Breast. 2024 Apr 4;75:103729. doi: 10.1016/j.breast.2024.103729. Online ahead of print.ABSTRACTOver the past few decades, first-line therapy for treating advanced and metastatic HR+/HER2-breast cancer has transformed due to the introduction of adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). However, there is an unmet need for novel classes of endocrine therapy with superior efficacy to improve treatment outcomes and overcome CDK4/6i resistance. New generation selective estrogen receptor degraders (SERDs), orally administered and with higher bioavailability, could potentially be the novel ...
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Kleoniki Apostolidou Eleni Zografos Maria Alkistis Papatheodoridi Oraianthi Fiste Meletios Athanasios Dimopoulos Flora Zagouri Source Type: research
The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer
CONCLUSIONS: Nonadherence was high in the current sample, and significantly more likely in participants reporting overall severe symptoms. Clinicians should be aware of the scale of common side effects and facilitate open conversation about potential barriers to adherence. Follow-up care should include assessment of common symptoms and signpost patients to appropriate support or treatment when required. Future research should explore potential for a central symptom to act as a target for intervention, to relieve overall side effect burden and facilitate better medication adherence.PMID:38599048 | DOI:10.1016/j.breast.2024....
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Sommer Agnew Megan Crawford Iain MacPherson Victor Shiramizu Leanne Fleming Source Type: research
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature
CONCLUSION: The study showed that a subgroup of patients with a clinical high risk and a genomic low risk ER+/HER2-breast cancer benefits from NET resulting in BCS instead of a mastectomy. Additionally, NET may enable de-escalation in axillary treatment.PMID:38599047 | DOI:10.1016/j.breast.2024.103726 (Source: Breast)
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Josefien P van Olmen Chaja F Jacobs Sanne A L Bartels Claudette E Loo Joyce Sanders Marie-Jeanne T F D Vrancken Peeters Caroline A Drukker Frederieke H van Duijnhoven Marleen Kok Source Type: research
Apatinib beyond first progression is associated with prolonged overall survival in patients with advanced breast cancer: Results from an observational study
Exp Ther Med. 2024 Mar 14;27(5):200. doi: 10.3892/etm.2024.12488. eCollection 2024 May.ABSTRACTIn the present study, the efficacy and safety of a low dose of apatinib in the treatment of patients with advanced breast cancer (ABC) in a real-world setting were assessed, the impact of continuous anti-angiogenic therapy beyond progression was determined and the factors associated with efficacy were evaluated. A total of 63 patients with ABC who were treated with apatinib and for whom several lines of treatment had failed were retrospectively analyzed in Tangshan People's Hospital (Tangshan, China) between January 2016 and Octo...
Source: Experimental and Therapeutic Medicine - April 9, 2024 Category: General Medicine Authors: Jing Wang Jinghao Jia Jingjing Liu Xuemin Yao Zhiyong Yuan Source Type: research
Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
AbstractPurpose of ReviewYoung patients with breast cancer have unique survivorship needs, including fertility and family planning concerns, complications from iatrogenic menopause, and long-term quality-of-life issues. We aim to summarize the latest data on these side effects of cancer care to guide physicians in providing evidence-based survivorship care for this unique group of patients.Recent FindingsFertility preservation is safe prior to cancer treatment without any adverse impact on disease-free recurrence or overall survival. Pregnancy after breast cancer can be achieved safely; preliminary data from the POSITIVE t...
Source: Current Breast Cancer Reports - April 9, 2024 Category: Cancer & Oncology Source Type: research
Investigation of recurrence prediction ability of EndoPredict < sup > ® < /sup > using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict < sup > ® < /sup > from microarray data from fresh-frozen to FFPE tissues
CONCLUSIONS: EP using microarray data from FF tissues was useful in predicting distant recurrence risk in luminal breast cancer, and EP might be utilized in microarray data from FFPE tissues.PMID:38587783 | DOI:10.1007/s12282-024-01573-7 (Source: Breast Cancer)
Source: Breast Cancer - April 8, 2024 Category: Cancer & Oncology Authors: Akira Watanabe Ryo Tsunashima Chikage Kato Sae Kitano Saya Matsumoto Yoshiaki Sota Midori Morita Koichi Sakaguchi Yasuto Naoi Source Type: research
Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients
CONCLUSIONS: Women with stage I cancer, no chemotherapy, higher comorbidity burden, and history of chronic non-cancer medication use were less likely to adhere to AET. Taking steps to promote adherence in these groups of women may reduce their risk of recurrence.PMID:38589932 | DOI:10.1186/s13058-024-01819-4 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 8, 2024 Category: Cancer & Oncology Authors: Kirsten M Woolpert Julie A Schmidt Thomas P Ahern Cathrine F Hjorth D óra K Farkas Bent Ejlertsen Lindsay J Collin Timothy L Lash Deirdre P Cronin-Fenton Source Type: research
Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients
CONCLUSIONS: Women with stage I cancer, no chemotherapy, higher comorbidity burden, and history of chronic non-cancer medication use were less likely to adhere to AET. Taking steps to promote adherence in these groups of women may reduce their risk of recurrence.PMID:38589932 | DOI:10.1186/s13058-024-01819-4 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 8, 2024 Category: Cancer & Oncology Authors: Kirsten M Woolpert Julie A Schmidt Thomas P Ahern Cathrine F Hjorth D óra K Farkas Bent Ejlertsen Lindsay J Collin Timothy L Lash Deirdre P Cronin-Fenton Source Type: research
Dual-target inhibitors based on ER α: Novel therapeutic approaches for endocrine resistant breast cancer
Eur J Med Chem. 2024 Apr 7;270:116393. doi: 10.1016/j.ejmech.2024.116393. Online ahead of print.ABSTRACTEstrogen receptor alpha (ERα), a nuclear transcription factor, is a well-validated therapeutic target for more than 70% of all breast cancers (BCs). Antagonizing ERα either by selective estrogen receptor modulators (SERMs) or selective estrogen receptor degraders (SERDs) forms the foundation of endocrine therapy and has achieved great success in the treatment of ERα positive (ERα+) BCs. Unfortunately, despite initial effectiveness, endocrine resistance eventually emerges in up to 30% of ERα+ BC patients and remains ...
Source: European Journal of Medicinal Chemistry - April 8, 2024 Category: Chemistry Authors: Shuangshuang Xiong Ke Song Hua Xiang Guoshun Luo Source Type: research
The Influence of Pharmaceutical Care in Patients with Breast Cancer Receiving Adjuvant Endocrine Therapy
(Source: American Journal of Health Behavior)
Source: American Journal of Health Behavior - April 6, 2024 Category: Psychiatry & Psychology Authors: Zhu, Wanhu Chen, Juan Zhao, Xincai Ying, Xuexiang Le, Chun Tang, Fen Qiu, Yao Guo, Cheng Xu, Rong Zhang, Jianping Source Type: research
Innovative Surgical Approaches That Improve Individual Outcomes in Advanced Breast Cancer
Int J Womens Health. 2024 Mar 30;16:555-560. doi: 10.2147/IJWH.S447837. eCollection 2024.ABSTRACTBreast cancer is the most common cause of cancer death in women and the second cause in the general population. The incidence has increased over time. Women in developing countries often present at an advanced stage where initial surgery is not feasible. Short disease-free intervals, the number of metastatic organs and liver metastasis were consistently associated with poor overall survival. Surgery is an integral part of the therapeutic plan for locally advanced breast cancer. The integration of surgical care into the manageme...
Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Valerii Lu țenco Laura Rebegea Adrian Beznea George Tocu Monica Moraru Oana Mariana Mihailov Bogdan Mihnea Ciuntu Verginia Lu țenco Floris Cristian Stanculea Raul Mihailov Source Type: research
